Penumbra Inc
PEN- Exchange
- NYSE
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001321732
No open-market purchases or sales by Penumbra Inc insiders were filed in the last 90 days; 452 institutions reported holding it in 13F filings for Q2 2026, worth $10.8B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 30, 2026, 1:17 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 15, 2026 | Feb 18, 2025 | Feb 22, 2024 | Feb 23, 2023 | Feb 22, 2022 |
| Revenue | $1.40B | $1.19B | $1.06B | $847.1M | $747.6M |
| Cost of revenue | $461.2M | $439.6M | $375.9M | $311.9M | $272.2M |
| Gross profit | $942.4M | $755.0M | $682.6M | $535.2M | $475.4M |
| Operating expenses | $753.2M | $745.7M | $609.1M | $529.1M | $482.9M |
| Research and development | $89.8M | $94.8M | $84.4M | $79.4M | $104.6M |
| Selling, general and administrative | $663.4M | $574.0M | $506.5M | $449.7M | $378.3M |
| Operating income | $189.2M | $9.28M | $73.6M | $6.08M | -$7.50M |
| Interest expense | – | – | $1.74M | – | – |
| Income tax | $27.4M | $6.86M | -$11.3M | $5.89M | -$13.1M |
| Net income | $177.7M | $14.0M | $91.0M | -$2.00M | $5.28M |
| EPS, basic | $4.57 | $0.36 | $2.37 | $-0.05 | $0.14 |
| EPS, diluted | $4.52 | $0.36 | $2.32 | $-0.05 | $0.14 |
| Weighted shares, basic | 38.9M | 38.6M | 38.4M | 37.8M | 36.8M |
| Weighted shares, diluted | 39.3M | 39.3M | 39.2M | 37.8M | 37.9M |
| Margins and growth | |||||
| Gross margin | 67.1% | 63.2% | 64.5% | 63.2% | 63.6% |
| Operating margin | 13.5% | 0.8% | 6.9% | 0.7% | -1.0% |
| Net margin | 12.7% | 1.2% | 8.6% | -0.2% | 0.7% |
| Revenue growth, year over year | +17.5% | +12.9% | +25.0% | +13.3% | +33.4% |
| Net income growth, year over year | +1,168.1% | −84.6% | – | −137.9% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 15, 2026 | Feb 18, 2025 | Feb 22, 2024 | Feb 23, 2023 | Feb 22, 2022 |
| Cash and equivalents | $186.9M | $324.4M | $167.5M | $69.9M | $59.4M |
| Accounts receivable | $190.0M | $167.7M | $201.8M | $203.4M | $133.9M |
| Inventory | $431.5M | $406.7M | $388.0M | $334.0M | $263.5M |
| Total current assets | $1.22B | $951.1M | $915.4M | $755.7M | $681.5M |
| Property, plant and equipment | $117.4M | $62.6M | $72.7M | $65.0M | $58.9M |
| Goodwill | $166.8M | $165.8M | $166.3M | $166.0M | $166.4M |
| Intangible assets | $6.19M | $6.51M | $71.1M | $81.2M | $90.6M |
| Total assets | $1.83B | $1.53B | $1.56B | $1.37B | $1.24B |
| Accounts payable | $34.7M | $31.3M | $27.2M | $26.7M | $13.4M |
| Total current liabilities | $183.1M | $158.3M | $151.1M | $144.9M | $123.2M |
| Total liabilities | $398.9M | $382.3M | $377.4M | $372.0M | $290.3M |
| Shareholders' equity | $1.43B | $1.15B | $1.18B | $998.9M | $953.9M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 15, 2026 | Feb 18, 2025 | Feb 22, 2024 | Feb 23, 2023 | Feb 22, 2022 |
| Operating cash flow | $238.7M | $168.5M | $97.3M | -$55.7M | $9.50M |
| Capital expenditures | $63.7M | $21.2M | $15.2M | $19.3M | $21.2M |
| Free cash flow | $174.9M | $147.3M | $82.1M | -$75.0M | -$11.7M |
| Depreciation and amortization | $17.5M | $23.7M | $27.3M | $24.3M | $16.4M |
| Stock-based compensation | $59.2M | $46.2M | $50.5M | $37.4M | $65.8M |
| Share buybacks | $0 | $100.4M | – | – | – |
| Investing cash flow | -$404.6M | $77.6M | -$16.1M | $54.8M | -$21.7M |
| Financing cash flow | $26.5M | -$87.0M | $16.2M | $11.6M | $836.0K |
| Net change in cash | -$137.5M | $156.9M | $97.6M | $10.5M | -$10.3M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 4.2% | 3.9% | 4.8% | 4.4% | 8.8% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.